Forgot Password?
Return to Course Listing

CME: Male Osteoporosis Management: Advances in Pharmacotherapy


Activity Description / Statement of Need:

In this online, self-learning activity:


Osteoporosis is characterized by low bone mass and deterioration of bone tissues, which leads to an increased risk of skeletal fractures.Although osteoporosis is generally considered as a women’s health issue and often overlooked problem in men,osteoporosis in men is also an important public health issue, and its prevalence is increasing as the general population ages( – rising to 11% in men by age 80. Around 1 to 2 million men in the United States have been estimated to have clinical osteoporosis, and an additional 8 to 13 million men identified to have low bone mass.In sum, 35% of men are considered to have low bone density by age 50, and that number rises to 53% by age 80.(3) These numbers have practical consequences, as the risk of fracture increases with age. Not only are fractures of the vertebrae, hip, and humerus associated with complications that include pain, kyphosis, intra-abdominal compression, impaired gastrointestinal nutrition, depression, loss of mobility and autonomy, and a lower quality of life,but hip fracture in particular is associated a poor prognosis,including a 40% return to prefracture level of independence, 20% rate of long-term care requirements by patients, and the strongest correlation with mortality.

Target Audience:

The following healthcare professionals: primary care physicians and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with male osteoporosis.

Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.

Release Date: April 30, 2018 -- Expiration Date: April 30, 2020

Faculty: Maria Skamagas, MD


Introduction content: cursory refresher and review of male osteoporosis

  • Epidemiology
  • Defining clinical features
  • Risk factors
  • Statistics
  • Guidance on screening criteria in men: DXA, FRAX
  • Patient cases

Treatment options

  • Goal of treatments
    • A review of present pharmacotherapy; the roles of:
    • RANKL inhibitors
    • Bisphosphonates
    • Parathyroid hormone-related protein analogs
    • Testosterone therapy
    • Barriers to optimal care in male patients with Osteoporosis
  • Investigational therapies
  • Lifestyle factors and risk factor modification

Learning Objectives

By the end of the session the participant will be able to:

  • Apply screening criteria for male osteoporosis to a given patient
  • Describe the criteria for initiation of pharmacotherapy for osteoporosis treatment and prevention and apply them to a patient case
  • Identify present pharmacotherapeutic treatments for management of male osteoporosis, and describe their mechanisms of action and place in therapy
  • Describe investigational pharmacotherapeutic treatments for management of male osteoporosis, and describe their mechanisms of action and likely place in therapy
  • Describe the challenges associated with treating patients with male osteoporosis, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat and prevent osteoporosis and apply the information in optimizing patient care in a patient case


ACCME Activity #201226429


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Dr. Skamagas, MD, Assistant Professor, Icahn School of Medicine, New York, NY has received financial compensation for market research from Inspired Opinions,  Schlesinger Associates.

Disclosures of Peer Reviewer: Eric Goldberg, MD has no relevant financial disclosures.

Disclosures of Peer Reviewer: George Sarka, MD discloses that he has received honorarium as a speaker for Genzyme.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Optimizing Primary and Secondary Fracture Prevention in Men with Osteoporosis

Chronic Idiopathic Constipation (CIC): Optimizing Pharmacotherapeutic Management Strategies

Frontiers in the Pharmacotherapeutic Management of Osteoporosis